News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus

Study Status:

Not yet active

Contact Information:

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to demonstrate that the efficacy of Afrezza is noninferior to RAA injections, when both are in combination with a basal insulin, as measured by the change in HbA1c from baseline to Week 26 in pediatric subjects ≥4 and <18 years of age with T1DM or T2DM.

Information: 

Principal Investigator
Surya N. Mulukutla, MD
Co-PI
Luis Cantu Jr.
Sponsor
MannKind Corporation
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram